Identification and validation of hub genes involved in foam cell formation and atherosclerosis development
Bioinformatics
Cardiovascular disease (CVD)
Foam cells
Lipid metabolism
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
06
2023
accepted:
27
08
2023
medline:
10
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
Foam cells play crucial roles in all phases of atherosclerosis. However, until now, the specific mechanisms by which these foam cells contribute to atherosclerosis remain unclear. We aimed to identify novel foam cell biomarkers and interventional targets for atherosclerosis, characterizing their potential mechanisms in the progression of atherosclerosis. Microarray data of atherosclerosis and foam cells were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expression genes (DEGs) were screened using the "LIMMA" package in R software. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO) annotation were both carried out. Hub genes were found in Cytoscape after a protein-protein interaction (PPI) enrichment analysis was carried out. Validation of important genes in the GSE41571 dataset, cellular assays, and tissue samples. A total of 407 DEGs in atherosclerosis and 219 DEGs in foam cells were identified, and the DEGs in atherosclerosis were mainly involved in cell proliferation and differentiation. CSF1R and PLAUR were identified as common hub genes and validated in GSE41571. In addition, we also found that the expression of CSF1R and PLAUR gradually increased with the accumulation of lipids and disease progression in cell and tissue experiments. CSF1R and PLAUR are key hub genes of foam cells and may play an important role in the biological process of atherosclerosis. These results advance our understanding of the mechanism behind atherosclerosis and potential therapeutic targets for future development.
Sections du résumé
Background
Foam cells play crucial roles in all phases of atherosclerosis. However, until now, the specific mechanisms by which these foam cells contribute to atherosclerosis remain unclear. We aimed to identify novel foam cell biomarkers and interventional targets for atherosclerosis, characterizing their potential mechanisms in the progression of atherosclerosis.
Methods
Microarray data of atherosclerosis and foam cells were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expression genes (DEGs) were screened using the "LIMMA" package in R software. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO) annotation were both carried out. Hub genes were found in Cytoscape after a protein-protein interaction (PPI) enrichment analysis was carried out. Validation of important genes in the GSE41571 dataset, cellular assays, and tissue samples.
Results
A total of 407 DEGs in atherosclerosis and 219 DEGs in foam cells were identified, and the DEGs in atherosclerosis were mainly involved in cell proliferation and differentiation. CSF1R and PLAUR were identified as common hub genes and validated in GSE41571. In addition, we also found that the expression of CSF1R and PLAUR gradually increased with the accumulation of lipids and disease progression in cell and tissue experiments.
Conclusion
CSF1R and PLAUR are key hub genes of foam cells and may play an important role in the biological process of atherosclerosis. These results advance our understanding of the mechanism behind atherosclerosis and potential therapeutic targets for future development.
Identifiants
pubmed: 37810795
doi: 10.7717/peerj.16122
pii: 16122
pmc: PMC10557941
doi:
Substances chimiques
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Receptors, Colony-Stimulating Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16122Informations de copyright
©2023 Teng et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
J Natl Cancer Inst. 1999 May 19;91(10):869-74
pubmed: 10340907
Atherosclerosis. 2022 Jun;351:29-40
pubmed: 35365353
Front Cardiovasc Med. 2022 Aug 18;9:907665
pubmed: 36061537
BMC Med Genomics. 2023 May 12;16(1):100
pubmed: 37173673
J Med Biochem. 2020 Sep 02;39(3):372-383
pubmed: 33269026
FASEB J. 2023 May;37(5):e22933
pubmed: 37093709
Nat Med. 2011 Nov 07;17(11):1410-22
pubmed: 22064431
Circ Res. 2016 Feb 19;118(4):679-91
pubmed: 26892966
Sci Rep. 2023 May 26;13(1):8533
pubmed: 37237021
J Cardiovasc Transl Res. 2023 May 1;:
pubmed: 37126209
Circulation. 2012 May 15;125(19):2363-73
pubmed: 22586291
Front Cardiovasc Med. 2022 Jun 22;9:894879
pubmed: 35811739
Vascul Pharmacol. 2019 Jan;112:54-71
pubmed: 30115528
Hum Genomics. 2022 Nov 3;16(1):53
pubmed: 36329547
Front Immunol. 2020 Feb 21;11:284
pubmed: 32153588
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):910-8
pubmed: 23273713
Biomed Res Int. 2016;2016:9582430
pubmed: 27493969
Front Cardiovasc Med. 2022 Jul 07;9:888818
pubmed: 35872908
J Biol Chem. 2008 Dec 19;283(51):35745-55
pubmed: 18955491
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):272-9
pubmed: 25538208
Lancet Glob Health. 2020 May;8(5):e721-e729
pubmed: 32353319
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):220-233
pubmed: 33086870
Nat Rev Immunol. 2013 Oct;13(10):709-21
pubmed: 23995626
Ann Transl Med. 2023 Mar 15;11(5):189
pubmed: 37007574
Atherosclerosis. 2013 Jan;226(1):74-81
pubmed: 23122912
PLoS Genet. 2015 Apr 02;11(4):e1005061
pubmed: 25835000
J Clin Invest. 2022 Dec 15;132(24):
pubmed: 36194491
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
PeerJ. 2022 Feb 08;10:e12846
pubmed: 35186462
Cell Metab. 2011 Jan 5;13(1):11-22
pubmed: 21195345
Sci Rep. 2023 Apr 13;13(1):6054
pubmed: 37055467
J Hypertens. 2017 Apr;35(4):810-821
pubmed: 28253220
J Leukoc Biol. 2009 Feb;85(2):278-88
pubmed: 19004987
Front Immunol. 2019 Apr 24;10:837
pubmed: 31068933
J Proteom Genom Res. 2017;2(1):1-12
pubmed: 29367937
Eur J Vasc Endovasc Surg. 2012 Nov;44(5):491-7
pubmed: 22975154
Circulation. 2010 Aug 3;122(5):452-4
pubmed: 20644011
Expert Rev Cardiovasc Ther. 2006 Sep;4(5):703-9
pubmed: 17081092
Lipids Health Dis. 2022 Sep 10;21(1):87
pubmed: 36088434
Vascul Pharmacol. 2023 Jun;150:107172
pubmed: 37075932
J Immunol Res. 2020 Jan 29;2020:8131754
pubmed: 32411803
Atherosclerosis. 2020 Aug;307:11-15
pubmed: 32702535
Circulation. 2022 Feb 22;145(8):e153-e639
pubmed: 35078371
Int Immunopharmacol. 2022 Dec;113(Pt A):109260
pubmed: 36252496
Nat Rev Dis Primers. 2019 Aug 16;5(1):56
pubmed: 31420554
Atherosclerosis. 2006 Jun;186(2):282-90
pubmed: 16153649
J Lipid Res. 2010 Jul;51(7):1962-70
pubmed: 20194110
Front Immunol. 2022 Sep 23;13:956078
pubmed: 36211422
J Am Coll Cardiol. 2018 Jul 17;72(3):300-310
pubmed: 30012324
Cells. 2020 Dec 24;10(1):
pubmed: 33374145
Vascul Pharmacol. 2020 May - Jun;128-129:106675
pubmed: 32200116
Atherosclerosis. 2017 Sep;264:108-114
pubmed: 28728756
Bioinformatics. 2016 Dec 15;32(24):3798-3806
pubmed: 27578803
BMC Med Genomics. 2023 May 13;16(1):102
pubmed: 37179331
Cardiovasc Res. 2012 Jul 15;95(2):165-72
pubmed: 22345306
Thromb Haemost. 1999 Apr;81(4):594-600
pubmed: 10235446
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Cells. 2020 Mar 01;9(3):
pubmed: 32121535
Circulation. 2012 Apr 3;125(13):1673-83
pubmed: 22388324
Front Pharmacol. 2022 Oct 04;13:977490
pubmed: 36267275
J Biosci. 2013 Jun;38(2):311-5
pubmed: 23660665